Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

MaaT's bid to overturn microbiome approval refusal suffers setback

15 September 2026 · By · Wire by Fusion42

Published

15 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Europe

◆ Source

Read at european-biotechnology.com →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

MaaT Pharma received a negative opinion from EMA's CHMP after requesting re-examination of its microbiome therapy approval refusal, intensifying financial pressures on the biotech.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Microbiome therapy founders face tougher regulatory rejection in Europe. You must prepare for longer approval times and plan finances accordingly.

◆ Coverage

1 source · 15 Sep 2026

◆ Related on Wire

◆ Topics

Biotechemamicrobiomedrug-approvalbiotechregulatory-setback